Hasin Deborah, Walsh Claire
New York State Psychiatric Institute, New York, NY 10032, USA.
Department of Epidemiology, Mailman School of Public Health, Columbia University Medical Center, New York, NY 10032, USA.
J Clin Med. 2020 Dec 23;10(1):15. doi: 10.3390/jcm10010015.
The landscape of attitudes, legal status and patterns of use of cannabis is rapidly changing in the United States and elsewhere. Therefore, the primary aim of this narrative review is to provide a concise overview of the literature on the comorbidity of cannabis use and cannabis use disorder (CUD) with other substance use and psychiatric disorders, and to use this information to accurately guide future directions for the field.
A literature review of PubMed was conducted for studies relating to cannabis use, CUD, and a co-occurring psychiatric disorder. To provide an overview of representative data, the literature review focused on national-level, population-based work from the National Epidemiologic Survey on Alcohol and Related Conditions (NESARC) and National Survey on Drug Use and Health (NSDUH) surveys. Considering rapidly changing cannabis laws, recent (past five-year) studies were addressed.
A strong body of literature shows associations between cannabis use and CUD with other drug use, psychosis, mood disorders, anxiety disorders, and personality disorders. The strongest evidence of a potential causal relationship exists between cannabis use and psychotic disorders. While some evidence shows potential directionality between cannabis use and mood and anxiety disorders, results are inconsistent. Studies have established higher rates of CUD among those with personality disorders, but little about the specifics of this relationship is understood.
Although the general population in the United States increasingly perceives cannabis to be a harmless substance, empirical evidence shows that cannabis use is associated both with CUD and comorbid psychiatric illness. However, there is mixed evidence regarding the role of cannabis in the etiology, course, and prognosis of a co-occurring disorder across all categories of psychiatric disorders. Future research should expand on the existing body of literature with representative, longitudinal data, in order to better understand the acute and long-term effects of cannabis on comorbid psychiatric illness.
在美国及其他地区,大麻的使用态度、法律地位和使用模式正在迅速变化。因此,本叙述性综述的主要目的是简要概述关于大麻使用及大麻使用障碍(CUD)与其他物质使用和精神障碍共病的文献,并利用这些信息准确指导该领域未来的研究方向。
对PubMed上有关大麻使用、CUD和共病精神障碍的研究进行文献综述。为了概述代表性数据,文献综述聚焦于来自全国酒精及相关状况流行病学调查(NESARC)和全国药物使用和健康调查(NSDUH)的国家级、基于人群的研究。考虑到大麻法律的迅速变化,纳入了近期(过去五年)的研究。
大量文献表明,大麻使用和CUD与其他药物使用、精神病、情绪障碍、焦虑障碍及人格障碍之间存在关联。大麻使用与精神障碍之间存在潜在因果关系的证据最为确凿。虽然一些证据显示大麻使用与情绪和焦虑障碍之间存在潜在的方向性,但结果并不一致。研究表明人格障碍患者中CUD的发生率较高,但对这种关系的具体情况了解甚少。
尽管美国普通民众越来越认为大麻是一种无害物质,但实证证据表明,大麻使用与CUD及共病精神疾病有关。然而,关于大麻在各类精神障碍共病的病因、病程和预后中的作用,证据不一。未来的研究应以具有代表性的纵向数据扩展现有文献,以便更好地了解大麻对共病精神疾病的急性和长期影响。